Phase 2
N=24
Effects of PRK 124 Lotion in Acne Rosacea
Acne Rosacea
Bottom Line
View on ClinicalTrials.gov: NCT00580723 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcome: Primary: Erythema Severity — 44.53 Erythema percent improvement
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- PRK 124 (Other)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- University of California, Irvine
- Primary completion
- Feb 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Erythema Severity |
44.53 | — |
| PRIMARY Inflammatory Lesion Count |
89 | — |
| PRIMARY Telangiectasia Severity |
27.88 | — |
| SECONDARY Skin Tolerance |
— | — |
| SECONDARY Skin Photodamage |
— | — |
| SECONDARY Transepidermal Water Loss (TEWL) |
— | — |
| SECONDARY Cosmetic Acceptability |
— | — |
Summary
The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial rosacea.
Eligibility Criteria
Inclusion Criteria
- be at least 21 years old
- be in reasonably good health as defined by the study doctor
- have routine laboratory tests to evaluate your blood cell count, and kidney and liver function
- for females of child-bearing age, not be pregnant or nursing and have a negative urine pregnancy test (except if surgically sterile or at least 1 year menopausal)
- for females, agree to use medically acceptable forms of birth control throughout the entire study (medically acceptable forms of birth control include oral contraceptive ["the pill"], implants such as Norplant®, injectable progesterone [Depo-provera®], diaphragm and spermicide or condoms and spermicide)
- must have mild to moderate acne rosacea
- be willing to refrain from using non-approved lotions, moisturizer, cleansers or lotions on affected facial areas during the treatment period
- be capable of understanding and giving written, voluntary informed consent before study screening
- be willing to consent to facial photographs at baseline and each follow-up visit to monitor treatment with the test product.
Exclusion Criteria
- have a history or evidence of any chronic or reoccurring skin disease or disorder (e.g., psoriasis, eczema, etc.) affecting the face
- have known or suspected hypersensitivity to study treatment or any of its ingredients
- have used systemic retinoids within 6 months prior to study entry (e.g., acitretin, isotretinoin)
- have received treatment with systemic corticosteroids (e.g. prednisone) or antibiotics within 1 month
- have used topical treatment to the face with retinoids (e.g. tretinoin, adapalene), or antibiotics or corticosteroids, within 2 weeks prior to study entry
- are unwilling to use a sunscreen with an SPF of 30 during the study
- have participated in any clinical trial involving an investigational drug or cosmetic product or procedure within the past 30 days
Data sourced from ClinicalTrials.gov (NCT00580723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.